Clinical bottom line
Chronic pruritic dermatitis is a common and distressing complication in patients with diabetes mellitus, often complicating glycemic control and quality of life. Emerging systemic treatments targeting pruritus pathways show promise but remain underexplored specifically in diabetic populations. Current evidence on systemic antihyperglycemic agents such as glimepiride and semaglutide primarily addresses metabolic control rather than pruritus relief. Early-phase trials of novel antipruritic agents like KPL-716 indicate potential efficacy in chronic pruritic diseases but lack diabetes-specific data. Clinicians should cautiously consider systemic therapies for pruritic dermatitis in diabetes, balancing metabolic benefits with dermatologic outcomes, while awaiting robust, targeted clinical trials.
What the evidence shows
Diabetes mellitus is associated with multiple cutaneous manifestations, including chronic pruritic dermatitis, which may arise from xerosis, neuropathy, or inflammatory pathways. While systemic antihyperglycemic agents are well studied for glycemic control, their direct impact on pruritus is less clear.
Glimepiride, a sulfonylurea commonly used as initial therapy in type 2 diabetes, has demonstrated a favorable safety and efficacy profile in improving glycemic parameters (Ametov et al., 2013; Ruyatkina et al., 2012). However, these studies do not specifically assess effects on pruritus or skin inflammation. Similarly, oral semaglutide, a GLP-1 receptor agonist, has shown robust glycemic control and cardiovascular benefits (Somani et al., 2024), but data on dermatologic symptom modulation are lacking.
Novel systemic antipruritic agents, such as KPL-716, an anti-OSMRβ monoclonal antibody, have been investigated in chronic pruritic diseases with promising reductions in itch severity and improved tolerability (Kernel Networks Inc., 2019). Although these results are encouraging, the trial populations did not specifically include patients with diabetes mellitus, limiting direct applicability.
Additional studies on routine diabetic foot treatments highlight the importance of comprehensive skin care in diabetes to prevent complications, but do not address systemic antipruritic therapies (Udovichenko et al., 2014). Moreover, anxiolytic treatments in diabetic patients have been explored for their systemic effects but are not directly relevant to pruritic dermatitis management (Starostina et al., 2010).
Caveats and uncertainty
The evidence base for systemic treatments targeting chronic pruritic dermatitis in diabetes mellitus is sparse and indirect. Most antihyperglycemic drug trials focus on metabolic outcomes without detailed dermatologic endpoints. The pathophysiology of pruritus in diabetes is multifactorial, involving neuropathic, inflammatory, and xerotic components, complicating therapeutic targeting.
Novel antipruritic agents like KPL-716 require validation in diabetic cohorts to confirm efficacy and safety, as diabetes-related immune alterations and comorbidities may influence treatment response. Furthermore, long-term safety data on systemic antipruritic therapies in diabetes are lacking.
Heterogeneity in study designs, small sample sizes, and absence of randomized controlled trials specifically addressing pruritic dermatitis in diabetes limit the strength of current conclusions. Clinicians should remain vigilant for adverse effects and monitor glycemic control when initiating systemic therapies.
How this may change practice
Pending further evidence, dermatologists and endocrinologists should adopt a multidisciplinary approach to managing chronic pruritic dermatitis in diabetes, emphasizing optimized glycemic control, skin hydration, and avoidance of irritants.
Systemic antihyperglycemic agents should be selected primarily for metabolic indications, with awareness of their limited direct impact on pruritus. Emerging antipruritic biologics may become valuable adjuncts, but their use should currently be confined to clinical trials or specialist settings.
Routine assessment of pruritus severity and quality of life in diabetic patients can guide individualized treatment decisions. Collaboration between dermatology and diabetes care teams is essential to balance metabolic and dermatologic outcomes.
Future research should prioritize randomized controlled trials evaluating systemic antipruritic therapies specifically in diabetic populations, incorporating validated itch and skin quality endpoints.